NCT00000935View on ClinicalTrials.gov

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

Not specified

Primary Completion Date

June 30, 2003

Study Completion Date

June 30, 2003

Conditions
End-Stage Renal DiseaseKidney Transplantation
Interventions
BIOLOGICAL

Intravenous immune globulin (IVIG)

given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)

Trial Locations (1)

20850

Ann Limberger, Rockville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH